WO2005067405A3 - Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo - Google Patents

Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo Download PDF

Info

Publication number
WO2005067405A3
WO2005067405A3 PCT/KR2005/000186 KR2005000186W WO2005067405A3 WO 2005067405 A3 WO2005067405 A3 WO 2005067405A3 KR 2005000186 W KR2005000186 W KR 2005000186W WO 2005067405 A3 WO2005067405 A3 WO 2005067405A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitiligo
prevention
treatment
screening
prognosis
Prior art date
Application number
PCT/KR2005/000186
Other languages
French (fr)
Other versions
WO2005067405A2 (en
Inventor
Ai Young Lee
Nan Hyung Kim
Original Assignee
School Foundation Eulji
Ai Young Lee
Nan Hyung Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Foundation Eulji, Ai Young Lee, Nan Hyung Kim filed Critical School Foundation Eulji
Publication of WO2005067405A2 publication Critical patent/WO2005067405A2/en
Publication of WO2005067405A3 publication Critical patent/WO2005067405A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23N—MACHINES OR APPARATUS FOR TREATING HARVESTED FRUIT, VEGETABLES OR FLOWER BULBS IN BULK, NOT OTHERWISE PROVIDED FOR; PEELING VEGETABLES OR FRUIT IN BULK; APPARATUS FOR PREPARING ANIMAL FEEDING- STUFFS
    • A23N17/00—Apparatus specially adapted for preparing animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A23K10/32—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from hydrolysates of wood or straw
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/207—Pigmentation disorders

Abstract

The present invention relates to methods and kits for screening responsiveness to drugs effective in treatment or prevention of vitiligo, methods and kits for screening active ingredients effective in treatment or prevention of vitiligo, and methods and kits for prognosis of vitiligo using eukaryotic translation initiation factor 4A1 (eIF4A1) gene, ribosomal protein L13 (L13) gene and mediator of RNA polymerase to transcription (MRT) gene.
PCT/KR2005/000186 2004-01-20 2005-01-20 Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo WO2005067405A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2004-0004256 2004-01-20
KR20040004256 2004-01-20

Publications (2)

Publication Number Publication Date
WO2005067405A2 WO2005067405A2 (en) 2005-07-28
WO2005067405A3 true WO2005067405A3 (en) 2005-09-15

Family

ID=34793288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/000186 WO2005067405A2 (en) 2004-01-20 2005-01-20 Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo

Country Status (2)

Country Link
KR (1) KR100672853B1 (en)
WO (1) WO2005067405A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100788241B1 (en) * 2007-01-22 2007-12-27 동국대학교 산학협력단 Method for screening materials for preventing or treating vitiligo
KR100951446B1 (en) * 2009-01-23 2010-04-07 동국대학교 산학협력단 Single nucleotide polymorphism of tslp allele for diagnosis of vitiligo susceptibility
KR101146597B1 (en) * 2010-03-16 2012-05-16 동국대학교 산학협력단 Composition for Diagnosis of Vitiligo
CN114591991B (en) * 2022-03-31 2023-05-09 西南交通大学 Method for preparing calcipotriol key chiral intermediate based on short-chain carbonyl reductase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20030059862A1 (en) * 2001-05-24 2003-03-27 Ruben Steven M. Antibodies against tumor necrosis factor delta (APRIL)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165709A (en) 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6324479B1 (en) * 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20030059862A1 (en) * 2001-05-24 2003-03-27 Ruben Steven M. Antibodies against tumor necrosis factor delta (APRIL)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LE POLE I.C. ET AL: "Altered Gene Expression in Melanocytes Exposed to 4 Tertiary Butyl Phenol (4-TBP): Upregulation of the A2b Adenosine Receptor.", J.INVEST DERMATOL., vol. 113, no. 5, November 1999 (1999-11-01), pages 725 - 731 *
LEE A.Y. ET AL: "All Trans-Retinoic Acid (ATRA) Elevated Eukaryotic Translation Initiation Factor 4A1 (eIF4A1) mRNA in ATRA-Responsive Vitiliginous Epidermis.", PIGMENT CELL RES., vol. 17, no. 6, December 2004 (2004-12-01), pages 659 - 667 *

Also Published As

Publication number Publication date
WO2005067405A2 (en) 2005-07-28
KR100672853B1 (en) 2007-01-22
KR20050076690A (en) 2005-07-26

Similar Documents

Publication Publication Date Title
WO2006031901A3 (en) SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2003102214A3 (en) Method for efficient rna interference in mammalian cells
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2006085906A3 (en) Method for the direct detection of diagnostic rna
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
EP1994142A4 (en) Methods and compositions for the rapid isolation of small rna molecules
WO2005105157A3 (en) INHIBITION OF HAIRLESS PROTEIN mRNA
EP2046990A4 (en) Method of denaturing and fragmenting dna or rna using ultrasound
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
WO2004027024A3 (en) Isolation of genetic molecules from a complex biological construct for use in genetic expression analysis
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
EP1884771A4 (en) Protein-immobilized membrane, method for immobilization of protein, enzyme-immobilized electrode, and biosensor
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
WO2005073380A3 (en) Regulated polymerase iii expression systems and related methods
WO2005067405A3 (en) Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo
EP1789592A4 (en) Method for identification and quantification of short or small rna molecules
WO2006047728A3 (en) Bmp gene and fusion protein
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
AU2003265884A1 (en) Target and method for inhibition of bacterial rna polymerase
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2007076143A3 (en) Species-specific primer sets and identification of species-specific dna sequences using genome fragment enrichment
WO2004053078A3 (en) METHODS FOR MODULATING IKKα ACTIVITY
WO2005122709A3 (en) Purification methods and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase